Management of Kaposi sarcoma: the role of interferon and thalidomide
Kaposi sarcoma (KS) remains the most commonly diagnosed cancer in HIV-infected patients. Although several chemotherapeutic agents have proven effective in controlling KS, the growing understanding of the factors contributing to the development of KS has provided a stronger rationale for using noncyt...
Gespeichert in:
| Veröffentlicht in: | Current opinion in oncology 2001-09, Vol.13 (5), p.374-381 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 5 |
| container_start_page | 374 |
| container_title | Current opinion in oncology |
| container_volume | 13 |
| creator | Krown, Susan E |
| description | Kaposi sarcoma (KS) remains the most commonly diagnosed cancer in HIV-infected patients. Although several chemotherapeutic agents have proven effective in controlling KS, the growing understanding of the factors contributing to the development of KS has provided a stronger rationale for using noncytotoxic agents that influence the mechanisms involved in KS pathogenesis. Two such agents, interferon and thalidomide, have shown activity against KS in clinical trials and have the potential to influence multiple steps believed to be important in KS development and progression. Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action. |
| doi_str_mv | 10.1097/00001622-200109000-00010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71171058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71171058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3560-e814aff6edcd5bcfd6cf3df3c965ef22a6046f6f7e3578b8afb41bb4dd78c3d93</originalsourceid><addsrcrecordid>eNp1kU1PAyEQQInR2Fr9C2ZP3lZhWWDXm6mfscaLJt4IC4NdZZcK2zT-e6mtepLLMMybmeSBUEbwKcG1OMPpEF4UeZEirlOWr1_wDhoTRkkuMH3ZTXdc4rwSJR-hgxjfElHUuN5HI0IYY4KwMbp8UL16hQ76IfM2u1cLH9ssqqB9p86zYQ5Z8A7WtbYfIFgIvs9Ub1JJudb4rjVwiPaschGOtnGCnq-vnqa3-ezx5m56Mcs1ZRznUJFSWcvBaMMabQ3XlhpLdc0Z2KJQHJfcciuAMlE1lbJNSZqmNEZUmpqaTtDJZu4i-I8lxEF2bdTgnOrBL6MUhAiCWZXAagPq4GMMYOUitJ0Kn5JguTYofwzKX4Py22BqPd7uWDYdmL_GrbIElBtg5V0SEt_dcgVBzkG5YS7_-xn6BaGQe-0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71171058</pqid></control><display><type>article</type><title>Management of Kaposi sarcoma: the role of interferon and thalidomide</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Krown, Susan E</creator><creatorcontrib>Krown, Susan E</creatorcontrib><description>Kaposi sarcoma (KS) remains the most commonly diagnosed cancer in HIV-infected patients. Although several chemotherapeutic agents have proven effective in controlling KS, the growing understanding of the factors contributing to the development of KS has provided a stronger rationale for using noncytotoxic agents that influence the mechanisms involved in KS pathogenesis. Two such agents, interferon and thalidomide, have shown activity against KS in clinical trials and have the potential to influence multiple steps believed to be important in KS development and progression. Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action.</description><identifier>ISSN: 1040-8746</identifier><identifier>EISSN: 1531-703X</identifier><identifier>DOI: 10.1097/00001622-200109000-00010</identifier><identifier>PMID: 11555715</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Antiviral Agents - administration & dosage ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Combined Modality Therapy ; Cytokines - pharmacology ; Disease Progression ; HIV Infections - complications ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Interferon-alpha - administration & dosage ; Interferon-alpha - pharmacology ; Interferon-alpha - therapeutic use ; Sarcoma, Kaposi - drug therapy ; Sarcoma, Kaposi - pathology ; Thalidomide - pharmacology ; Thalidomide - therapeutic use</subject><ispartof>Current opinion in oncology, 2001-09, Vol.13 (5), p.374-381</ispartof><rights>2001 Lippincott Williams & Wilkins, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3560-e814aff6edcd5bcfd6cf3df3c965ef22a6046f6f7e3578b8afb41bb4dd78c3d93</citedby><cites>FETCH-LOGICAL-c3560-e814aff6edcd5bcfd6cf3df3c965ef22a6046f6f7e3578b8afb41bb4dd78c3d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11555715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krown, Susan E</creatorcontrib><title>Management of Kaposi sarcoma: the role of interferon and thalidomide</title><title>Current opinion in oncology</title><addtitle>Curr Opin Oncol</addtitle><description>Kaposi sarcoma (KS) remains the most commonly diagnosed cancer in HIV-infected patients. Although several chemotherapeutic agents have proven effective in controlling KS, the growing understanding of the factors contributing to the development of KS has provided a stronger rationale for using noncytotoxic agents that influence the mechanisms involved in KS pathogenesis. Two such agents, interferon and thalidomide, have shown activity against KS in clinical trials and have the potential to influence multiple steps believed to be important in KS development and progression. Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action.</description><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Cytokines - pharmacology</subject><subject>Disease Progression</subject><subject>HIV Infections - complications</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Sarcoma, Kaposi - pathology</subject><subject>Thalidomide - pharmacology</subject><subject>Thalidomide - therapeutic use</subject><issn>1040-8746</issn><issn>1531-703X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1PAyEQQInR2Fr9C2ZP3lZhWWDXm6mfscaLJt4IC4NdZZcK2zT-e6mtepLLMMybmeSBUEbwKcG1OMPpEF4UeZEirlOWr1_wDhoTRkkuMH3ZTXdc4rwSJR-hgxjfElHUuN5HI0IYY4KwMbp8UL16hQ76IfM2u1cLH9ssqqB9p86zYQ5Z8A7WtbYfIFgIvs9Ub1JJudb4rjVwiPaschGOtnGCnq-vnqa3-ezx5m56Mcs1ZRznUJFSWcvBaMMabQ3XlhpLdc0Z2KJQHJfcciuAMlE1lbJNSZqmNEZUmpqaTtDJZu4i-I8lxEF2bdTgnOrBL6MUhAiCWZXAagPq4GMMYOUitJ0Kn5JguTYofwzKX4Py22BqPd7uWDYdmL_GrbIElBtg5V0SEt_dcgVBzkG5YS7_-xn6BaGQe-0</recordid><startdate>200109</startdate><enddate>200109</enddate><creator>Krown, Susan E</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200109</creationdate><title>Management of Kaposi sarcoma: the role of interferon and thalidomide</title><author>Krown, Susan E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3560-e814aff6edcd5bcfd6cf3df3c965ef22a6046f6f7e3578b8afb41bb4dd78c3d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Cytokines - pharmacology</topic><topic>Disease Progression</topic><topic>HIV Infections - complications</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Sarcoma, Kaposi - pathology</topic><topic>Thalidomide - pharmacology</topic><topic>Thalidomide - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Krown, Susan E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krown, Susan E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Kaposi sarcoma: the role of interferon and thalidomide</atitle><jtitle>Current opinion in oncology</jtitle><addtitle>Curr Opin Oncol</addtitle><date>2001-09</date><risdate>2001</risdate><volume>13</volume><issue>5</issue><spage>374</spage><epage>381</epage><pages>374-381</pages><issn>1040-8746</issn><eissn>1531-703X</eissn><abstract>Kaposi sarcoma (KS) remains the most commonly diagnosed cancer in HIV-infected patients. Although several chemotherapeutic agents have proven effective in controlling KS, the growing understanding of the factors contributing to the development of KS has provided a stronger rationale for using noncytotoxic agents that influence the mechanisms involved in KS pathogenesis. Two such agents, interferon and thalidomide, have shown activity against KS in clinical trials and have the potential to influence multiple steps believed to be important in KS development and progression. Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>11555715</pmid><doi>10.1097/00001622-200109000-00010</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8746 |
| ispartof | Current opinion in oncology, 2001-09, Vol.13 (5), p.374-381 |
| issn | 1040-8746 1531-703X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71171058 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Combined Modality Therapy Cytokines - pharmacology Disease Progression HIV Infections - complications Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Interferon-alpha - administration & dosage Interferon-alpha - pharmacology Interferon-alpha - therapeutic use Sarcoma, Kaposi - drug therapy Sarcoma, Kaposi - pathology Thalidomide - pharmacology Thalidomide - therapeutic use |
| title | Management of Kaposi sarcoma: the role of interferon and thalidomide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T04%3A47%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Kaposi%20sarcoma:%20the%20role%20of%20interferon%20and%20thalidomide&rft.jtitle=Current%20opinion%20in%20oncology&rft.au=Krown,%20Susan%20E&rft.date=2001-09&rft.volume=13&rft.issue=5&rft.spage=374&rft.epage=381&rft.pages=374-381&rft.issn=1040-8746&rft.eissn=1531-703X&rft_id=info:doi/10.1097/00001622-200109000-00010&rft_dat=%3Cproquest_cross%3E71171058%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71171058&rft_id=info:pmid/11555715&rfr_iscdi=true |